Ascendis Pharma A (ASND) Enterprise Value (2015 - 2026)

On a TTM basis, Ascendis Pharma A's Enterprise Value came in at $12.78 billion as of Jun 30, 2026, up 112.7% year-over-year; for the year ended Dec 31, 2025, it came in at $12.52 billion, up 79.8% from the prior year.

• Annual Enterprise Value has increased for three straight years, with a five-year compound annual growth rate of 9.0% (years ended Dec 2020 to Dec 2025).
• Across earlier years, Enterprise Value came in at $6.96 billion in the year ended Dec 31, 2024 (+1.7%), $6.84 billion in the year ended Dec 31, 2023 (+5.4%), $6.49 billion in the year ended Dec 31, 2022 (-7.6%) and $7.03 billion in the year ended Dec 31, 2021 (-13.6%).
• The figure for the quarter ended Jun 30, 2026 is the highest quarterly Enterprise Value in data going back to the quarter ended Mar 31, 2015.
• On a year-over-year basis, Enterprise Value has increased for five consecutive quarters, with growth averaging 41.3% over the last eight quarters.
• Peak year-over-year performance for Enterprise Value in the last five years was growth of 79.1% in the quarter ended Dec 31, 2025, against a decline of 31.5% in the quarter ended Sep 30, 2022 at the low end.
• Per Business Quant, the preceding three quarters came in at $13.51 billion (quarter ended Mar 31, 2026), $12.5 billion (quarter ended Dec 31, 2025) and $10.64 billion (quarter ended Sep 30, 2025).